Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1 R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms.

Copyright Nasdaq. Minimum 15 minutes delayed.

Events

Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

~ Phase 2 Data in Refractory Chronic Cough Expected in October 2018 ~ ~ Phase 2 Data in Psoriasis Expected December 2018 or January 2019 ~ ~ New Phase 2 Study in Chronic Pruritus of Unknown Origin Expected to Start in Q4 2018 ~ REDWOOD CITY, Calif. , Aug.

Menlo Therapeutics to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough,

Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatment

Results Presented at the International Investigative Dermatology Meeting REDWOOD CITY, Calif. , May 21, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with